Table 2 Treatment-related adverse events
All patients (N = 56) | ||
|---|---|---|
Any grade | Grade 3 or 4 | |
Anemia | 48 (85.7%) | 2 (3.6%) |
Asthenia | 44 (78.6%) | 3 (5.4%) |
White blood cell count decreased | 40 (71.4%) | 9 (16.1%) |
Rash | 40 (71.4%) | 2 (3.6%) |
Neutrophil count decreased | 37 (66.1%) | 14 (25.0%) |
Alopecia | 36 (64.3%) | 0 |
Alanine aminotransferase increased | 28 (50.0%) | 1 (1.8%) |
Aspartate aminotransferase increased | 26 (46.4%) | 1 (1.8%) |
Platelet count decreased | 19 (33.9%) | 2 (3.6%) |
Nausea | 19 (33.9%) | 0 |
Vomiting | 18 (32.1%) | 1 (1.8%) |
Neurotoxicity | 16 (28.6%) | 3 (5.4%) |
Pyrexia | 16 (28.6%) | 0 |
Gingival bleeding | 16 (28.6%) | 0 |
Constipation | 14 (25.0%) | 0 |
Hypoesthesia | 14 (25.0%) | 0 |
Diarrhea | 13 (23.2%) | 1 (1.8%) |
Decreased appetite | 12 (21.4%) | 1 (1.8%) |
Gamma-glutamyltransferase increased | 11 (19.6%) | 3 (5.4%) |
Bilirubin conjugated increased | 11 (19.6%) | 1 (1.8%) |
Abdominal pain upper | 10 (17.9%) | 0 |
Proteinuria | 9 (16.1%) | 0 |
Infusion related reaction | 8 (14.3%) | 1 (1.8%) |
Blood bilirubin increased | 7 (12.5%) | 1 (1.8%) |
Edema peripheral | 7 (12.5%) | 1 (1.8%) |
Mouth hemorrhage | 7 (12.5%) | 0 |
